Multi-year collaboration focuses on development of biodegradable antimicrobial peptides with broad application possibilities in the areas of skin care and healthcare
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Strengthening capabilities in Peptide Therapeutics and CDMO services
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Subscribe To Our Newsletter & Stay Updated
